news
CHMP meeting highlights – January 2025
In its January meeting, the EMA’s human medicines committee recommended eight new medicines, including biosimilars and a new vaccine.
List view / Grid view
Alzheimer's
news
New mass spectrometry Chapter could “revolutionise” biopharma quality assurance
Launch of the USP general method chapter signals a breakthrough in pharmaceutical drug impurity control, according to biopharma experts.
news
UK Clinical Trial Application submitted for amyloid-targeting drug
The Clinical Trial Application sent to the MHRA is for a combination drug with the potential to become a cost-effective treatment against early Alzheimer’s disease.
news
New data suggests novel mAb could delay progression of early Alzheimer’s
Full results from the “first Phase III study of a disease-modifying therapy to replicate the positive clinical results observed in a previous study” have been published in JAMA.
news
Big Pharma inventory management trends revealed
Rapid growth of Big Pharma manufacturer inventories fail to prevent medicine shortages, a 2022 report has highlighted.
news
Potential blockbuster drugs to watch in 2023
Lecanemab for Alzheimer's and the first potential gene therapy primed for US launch for haemophilia A are two potential blockbuster Drugs to Watch™, says a 2023 report.
news
Alzheimer’s therapeutics market to reach $6.8 billion by 2032
A large patient population and limited treatment options are expected to expand the Alzheimer’s therapeutics market at a CAGR of 9.3 percent, suggested a report.
news
Nanohybrid drug delivery vehicle could help treat Alzheimer’s
The chitosan drug delivery vehicle could be used for administering polyphenol ellagic acid (EA), a potential antioxidant treatment for Alzheimer’s and Parkinson’s.
news
‘Super-human’ red blood cells could revolutionise drug delivery
Modified ‘super-human’ red blood cells containing therapeutic compounds have been developed by researchers as a novel form of drug delivery.
news
FDA sends warning letter to company illegally selling CBD products
A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.
article
Shehnaaz Suliman Theravance Biopharma: ‘Being a healer in the face of inequality’
As part of EPR’s Women Inspiring Pharma series, Shehnaaz Suliman, SVP, Business Development and Strategy, Theravance Biopharma talks to Science Editor Dr Zara Kassam about fighting for human rights, inequality and the challenges women face in their careers...
news
Can aspirin treat Alzheimer’s?
A study shows low-dose aspirin may aid removal of harmful amyloid plaque in the brain...
news
MRC secures £40million for UK Dementia Research Institute building
A landmark £40million has been awarded to the UK Dementia Research Institute, via the Medical Research Council, for a new iconic hub building at University College London...
news
3F4AP tracer can measure demyelination in multiple sclerosis
PET imaging may improve diagnosis and monitoring for MS patients...
news
Multi-million funding for cryo-EM to boost structural biology revolution
US science minister announce new multi-million-pound commitment to boost the burgeoning field of cryo-electron microscopy (cryo-EM) in the UK.
